Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Novo Nordisk current and future product portfolio covers the type 2 diabetes treatment cascade¹ Overview of current and future products in Novo Nordisk's diabetes portfolio Second generation analogues First generation analogues Human insulin When basal insulin is not enough When metformin is not enough When it's time for insulin Once-daily optimisation Mealtime insulin control Slide 41 oral semaglutide OZEMPİC TRESIBA Xultophy RYZODEG Fiasp fast-acting insulin aspart semaglutide injection or VICTOZAⓇ LevemirⓇ Novo Mix® Novo Rapid or Insulatard® Mixtard® 30 ActrapidⓇ 1 Pending clinical development programmes and regulatory processes for oral semaglutide changing diabetes® novo nordisk

View entire presentation